Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Eledon Pharmaceuticals Inc (NASDAQ: ELDN) closed the day trading at $1.44 up 3.60% from the previous closing price of $1.39. In other words, the price has increased by $3.60 from its previous closing price. On the day, 1.54 million shares were traded. ELDN stock price reached its highest trading level at $1.49 during the session, while it also had its lowest trading level at $1.36.
Ratios:
For a better understanding of ELDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On January 28, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $9.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELDN now has a Market Capitalization of 108049344 and an Enterprise Value of -6376614.
Stock Price History:
The Beta on a monthly basis for ELDN is 1.05, which has changed by -0.64089775 over the last 52 weeks, in comparison to a change of 0.1028198 over the same period for the S&P500. Over the past 52 weeks, ELDN has reached a high of $5.08, while it has fallen to a 52-week low of $1.38. The 50-Day Moving Average of the stock is -48.93%, while the 200-Day Moving Average is calculated to be -53.95%.
Shares Statistics:
Over the past 3-months, ELDN traded about 2.05M shares per day on average, while over the past 10 days, ELDN traded about 3610910 shares per day. Insiders hold about 8.46% of the company’s shares, while institutions hold 54.68% stake in the company. Shares short for ELDN as of 1761868800 were 4281446 with a Short Ratio of 2.09, compared to 1759190400 on 6691429. Therefore, it implies a Short% of Shares Outstanding of 4281446 and a Short% of Float of 7.99.
Earnings Estimates
Eledon Pharmaceuticals Inc (ELDN) is presently subject to a detailed evaluation by 5.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.17 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.59 and -$0.7 for the fiscal current year, implying an average EPS of -$0.63. EPS for the following year is -$1.04, with 4.0 analysts recommending between -$0.72 and -$1.31.
